scispace - formally typeset
J

Juanita Romero-Diaz

Researcher at University Health Network

Publications -  94
Citations -  4861

Juanita Romero-Diaz is an academic researcher from University Health Network. The author has contributed to research in topics: Medicine & Lupus erythematosus. The author has an hindex of 24, co-authored 77 publications receiving 2804 citations. Previous affiliations of Juanita Romero-Diaz include University of Texas Health Science Center at Houston & National Institute of Nutrition, Hyderabad.

Papers
More filters
Journal ArticleDOI

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

Martin Aringer, +63 more
TL;DR: To develop new classification criteria for systemic lupus erythematosus (SLE) jointly supported by the European League Against Rheumatism and the American College of Rheumatology (ACR).
Journal ArticleDOI

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

Martin Aringer, +66 more
TL;DR: These new classification criteria for systemic lupus erythematosus have excellent sensitivity and specificity, and were developed using rigorous methodology with multidisciplinary and international input.
Journal ArticleDOI

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Ian N. Bruce, +39 more
TL;DR: It is found that several potentially modifiable risk factors for damage accrual are identified and an integrated strategy to address these may improve long-term outcomes.
Journal ArticleDOI

The frequency and outcome of lupus nephritis: results from an international inception cohort study

John G. Hanly, +44 more
- 01 Feb 2016 - 
TL;DR: Despite current standard of care, nephritis was associated with ESRD and death, and renal insufficiency was linked to lower health-related quality of life.
Journal ArticleDOI

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.

TL;DR: In this paper, the authors evaluated the efficacy and safety of voclosporin for the treatment of lupus nephritis in a phase 3 trial, where patients were randomly assigned (1:1) to either oral vocosporin (23·7 mg twice daily) or placebo, on a background of mycophenolate mofetil (1 g twice daily), and rapidly tapered low-dose oral steroids, by using an interactive web response system.